Published in Braz J Med Biol Res on February 01, 2007
Mycobacterium leprae-host-cell interactions and genetic determinants in leprosy: an overview. Future Microbiol (2011) 1.00
Leprosy therapy, past and present: can we hope to eliminate it? Indian J Dermatol (2010) 0.93
ENLIST 1: An International Multi-centre Cross-sectional Study of the Clinical Features of Erythema Nodosum Leprosum. PLoS Negl Trop Dis (2015) 0.77
Expression of CD64 on Circulating Neutrophils Favoring Systemic Inflammatory Status in Erythema Nodosum Leprosum. PLoS Negl Trop Dis (2016) 0.75
Leprosy in Denmark 1980-2010: a review of 15 cases. BMC Res Notes (2016) 0.75
A leprosy clinical severity scale for erythema nodosum leprosum: An international, multicentre validation study of the ENLIST ENL Severity Scale. PLoS Negl Trop Dis (2017) 0.75
Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med (1991) 4.43
The cutaneous infiltrates of leprosy: cellular characteristics and the predominant T-cell phenotypes. N Engl J Med (1982) 3.52
Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med (1993) 3.31
Defective gamma interferon production in leprosy. Reversal with antigen and interleukin 2. J Exp Med (1983) 2.61
Cellular responses to the intradermal injection of recombinant human gamma-interferon in lepromatous leprosy patients. Am J Pathol (1987) 2.18
Influence of delayed immune reactions on human epidermal keratinocytes. Proc Natl Acad Sci U S A (1986) 2.11
Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients. J Exp Med (1992) 1.63
The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis (1993) 1.55
The cutaneous infiltrates of leprosy. A transmission electron microscopy study. J Exp Med (1983) 1.51
[Progression to IDDM and islet cell antibodies (ICA; ICA-CF)]. J Pediatr (Rio J) (2003) 1.39
Use of ML dipstick as a tool to classify leprosy patients. Int J Lepr Other Mycobact Dis (2000) 1.16
Cytokine gene activation and modified responsiveness to interleukin-2 in the blood of tuberculosis patients. J Infect Dis (1993) 1.12
Cellular immune response to Mycobacterium leprae infection in human immunodeficiency virus-infected individuals. Infect Immun (1995) 1.10
Immunological cytokine correlates of protective immunity and pathogenesis in leprosy. Scand J Immunol (2000) 1.10
Cytokine mRNA expression in leprosy: a possible role for interferon-gamma and interleukin-12 in reactions (RR and ENL). Scand J Immunol (1999) 1.09
Reactional states in multibacillary Hansen disease patients during multidrug therapy. Rev Inst Med Trop Sao Paulo (1999) 1.09
Interleukin-10 promoter single-nucleotide polymorphisms as markers for disease susceptibility and disease severity in leprosy. Genes Immun (2004) 1.02
Use of PCR-mediated amplification of Mycobacterium leprae DNA in different types of clinical samples for the diagnosis of leprosy. J Med Microbiol (1993) 1.01
[Leprosy epidemiology in a cohort of household contacts in Rio de Janeiro (1987-1991)]. Cad Saude Publica (2000) 0.99
IFNG +874 T>A single nucleotide polymorphism is associated with leprosy among Brazilians. Hum Genet (2010) 0.99
Pentoxifylline decreases in vivo and in vitro tumour necrosis factor-alpha (TNF-alpha) production in lepromatous leprosy patients with erythema nodosum leprosum (ENL). Clin Exp Immunol (1998) 0.96
Serological response of patients with leprosy to a 28- to 30-kilodalton protein doublet from early cultures of Mycobacterium bovis BCG. J Clin Microbiol (1989) 0.96
HLA-DRB1*04 and DRB1*10 are associated with resistance and susceptibility, respectively, in Brazilian and Vietnamese leprosy patients. Genes Immun (2007) 0.94
Leprosy and AIDS: two cases of increasing inflammatory reactions at the start of highly active antiretroviral therapy. Eur J Clin Microbiol Infect Dis (2004) 0.93
Could fasting plasma glucose be used for screening high-risk outpatients for gestational diabetes mellitus? Diabetes Care (2001) 0.93
T cell immune responses to mycobacterial antigens in Brazilian tuberculosis patients and controls. Trans R Soc Trop Med Hyg (2005) 0.92
Bacterial and host-derived cationic proteins bind alpha2-laminins and enhance Mycobacterium leprae attachment to human Schwann cells. Microbes Infect (2000) 0.92
The role of indoleamine 2, 3-dioxygenase in lepromatous leprosy immunosuppression. Clin Exp Immunol (2011) 0.92
M. leprae-HIV co-infection: pattern of immune response in vivo and in vitro. Indian J Lepr (2000) 0.92
Serology and leprosy: immunoassays comparing immunoglobulin G antibody responses to 28- and 30-kilodalton proteins purified from Mycobacterium bovis BCG. J Clin Microbiol (1991) 0.91
Neutrophils isolated from leprosy patients release TNF-alpha and exhibit accelerated apoptosis in vitro. J Leukoc Biol (1999) 0.89
Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit M. leprae-induced TNFalpha production in vitro. Biomed Pharmacother (2002) 0.89
Effectiveness of BCG vaccination among leprosy contacts: a cohort study. Trans R Soc Trop Med Hyg (2008) 0.89
Binding of alpha2-laminins by pathogenic and non-pathogenic mycobacteria and adherence to Schwann cells. J Med Microbiol (2001) 0.89
Immunological responsiveness to M. leprae and BCG antigens in 98 leprosy patients and their household contacts. Braz J Med Biol Res (1988) 0.89
Effect of treatment on the cellular composition of cutaneous lesions in leprosy patients. Int J Lepr Other Mycobact Dis (1984) 0.89
Induction of apoptosis in monocytes by Mycobacterium leprae in vitro: a possible role for tumour necrosis factor-alpha. Immunology (2003) 0.88
DC-SIGN association with the Th2 environment of lepromatous lesions: cause or effect? J Pathol (2006) 0.87
Trypanosoma cruzi: the effect of variations in experimental conditions on the levels of macrophage infection in vitro. Parasitol Res (1989) 0.87
Thalidomide protects mice against LPS-induced shock. Braz J Med Biol Res (1997) 0.87
An immunohistochemical, clinical and electroneuromyographic correlative study of the neural markers in the neuritic form of leprosy. Braz J Med Biol Res (2006) 0.86
Sequential erythema nodosum leprosum and reversal reaction with similar lesional cytokine mRNA patterns in a borderline leprosy patient. Br J Dermatol (2001) 0.86
Influence of Mycobacterium leprae and its soluble products on the cutaneous responsiveness of leprosy patients to antigen and recombinant interleukin 2. Proc Natl Acad Sci U S A (1989) 0.86
High prevalence of vasomotor reflex impairment in newly diagnosed leprosy patients. Eur J Clin Invest (2005) 0.86
Effect of unique Mycobacterium leprae phenolic glycolipid-I (PGL-I) on tumour necrosis factor production by human mononuclear cells. Lepr Rev (2001) 0.85
Anti-inflammatory drugs block cytokine mRNA accumulation in the skin and improve the clinical condition of reactional leprosy patients. J Invest Dermatol (2000) 0.85
Expression and cytokine secretion in the states of immune reactivation in leprosy. Braz J Med Biol Res (1998) 0.83
In vitro tumor necrosis factor production by mononuclear cells from lepromatous leprosy patients and from patients with erythema nodosum leprosum. Clin Immunol Immunopathol (1993) 0.83
Long-term culture of multibacillary leprosy macrophages isolated from skin lesions: a new model to study Mycobacterium leprae-human cell interaction. Br J Dermatol (2007) 0.83
Mycobacterium leprae-induced interferon-gamma production by household contacts of leprosy patients: association with the development of active disease. J Infect Dis (1991) 0.83
Detection of in vitro interferon-gamma and serum tumour necrosis factor-alpha in multidrug-resistant tuberculosis patients. Clin Exp Immunol (2005) 0.82
Patterns of intracellular cytokines in CD4 and CD8 T cells from patients with mycobacterial infections. Braz J Med Biol Res (2004) 0.82
Different immunosuppressive mechanisms in multi-drug-resistant tuberculosis and non-tuberculous mycobacteria patients. Clin Exp Immunol (2013) 0.82
Impairments in multibacillary leprosy; a study from Brazil. Lepr Rev (2004) 0.81
Tumor necrosis factor-alpha promoter polymorphism TNF2 is associated with a stronger delayed-type hypersensitivity reaction in the skin of borderline tuberculoid leprosy patients. Immunogenetics (2001) 0.81
Effect of treatment on immune responsiveness in lepromatous leprosy patients. Lepr Rev (1990) 0.81
Interleukin-10-dependent down-regulation of interferon-gamma response to Leishmania by Mycobacterium leprae antigens during the clinical course of a coinfection. Braz J Med Biol Res (2012) 0.80
Increased Langerhans cell accumulation after mycobacterial stimuli. Histopathology (2007) 0.80
The use of pentoxifylline in the treatment of type 2 reactional episodes in leprosy. Indian J Lepr (2001) 0.80
T-helper cell subpopulations and the immune spectrum of leprosy. Int J Lepr Other Mycobact Dis (1989) 0.80
Tumor necrosis factor promoter polymorphism (TNF2) seems to protect against development of severe forms of leprosy in a pilot study in Brazilian patients. Int J Lepr Other Mycobact Dis (2000) 0.79
Interferon alpha treatment of patients with impaired interferon gamma signaling. J Clin Immunol (2013) 0.79
The diagnosis of leprosy among patients with symptoms of peripheral neuropathy without cutaneous lesions: a follow-up study. Arq Neuropsiquiatr (2000) 0.79
Development of giant reaction in response to PPD skin test in lepromatous leprosy patients. Int J Lepr Other Mycobact Dis (1993) 0.79
Further biochemical characterization of Mycobacterium leprae laminin-binding proteins. Braz J Med Biol Res (2001) 0.79
Two multidrug fixed-dosage treatment regimens with multibacillary leprosy patients. Indian J Lepr (1997) 0.78
Distribution of mononuclear phagocytes in glomerulonephritis with crescents. Nephron (1982) 0.78